Dynamic Purchasing System (DPS) For Medical Technology Innovation

Customers

We have a dedicated team on hand to support you through the process. For more information drop us an email and we’ll be in touch with a breakdown of the process.

DPS Customer Queries

DPSCustomerQueries@supplychain.nhs.uk

See our Useful Links section to view the latest Strategy Opportunities Document for medical technology innovations.

Suppliers

URN and how to get one – routes In

Our Unique Reference Number (URN*) is your gateway to participating in the DPS. Here’s how you can obtain one:

Innovation service: you can work with our innovation team if you are a supplier with products deemed innovative and aligned with the Department of Health and Social Care (DHSE) or National Institute for Health and Care Excellence (NICE) definition of disruptive innovation. Our innovation and category teams will assess your product and, if approved, provide you with a URN*.

Streamlined access: Our URN* acts as a key, allowing you as a supplier to navigate the tender process through our e-tendering platform, Jaggaer.

*URNs from NHS Supply Chain are different from URNs that may be supplied by other organisations, so it is very important that you use a URN provided by NHS Supply Chain’s innovation team.

Collaborative process: By engaging with the DPS, suppliers and NHS organisations work together to deliver solutions that address healthcare challenges effectively and efficiently.

The DPS simplifies procurement while maintaining rigorous governance, ensuring that all parties benefit from its transformative potential.

See our Useful Links section for guidance on making a submission through the Medical Technology DPS.

To enquire about any of the innovative technologies featured on this page, please contact:

Point of care molecular testing to determine antibiotic treatment of early-onset neonatal infection, late-onset neonatal infection for example sepsis, primarily in neonates. Could be used for renal, cystic fibrosis or other patients eligible for aminoglycosides that require a fast or urgent response.

The Genedrive (R) MT-RNR1 Product Range informs clinicians of  the presence or absence in a patient of a specific mitochondrial DNA variant (m.1555A or m.1555G). Results are presented as variant ‘Detected’ (m.1555G) or absent (m.1555A).  The MT-RNR1 m.1555A>G variant is associated with profound, irreversible bilateral and lifelong hearing loss when exposed to the aminoglycoside class of antibiotics (Antibiotic Induced Hearing Loss, AIHL). Alternative equally efficacious second line antibiotics such as cephalosporins are available to treat infections  in the event the variant is detected.

The Genedrive (R) MT-RNR1 test enables a result of a patient’s MT-RNR1 m1555A>G variant status within approximately 26 minutes, which is within the 1-hour time frame required by NICE guidance for administration of antibiotics in neonatal sepsis.

See our Useful Links section for NICE HTE6.

• The Quadsense system is a UK developed solution designed to address the challenge of balancing the patellofemoral joint during total knee surgery.
• The Quadsense system comprises two elements, a single use sensor, and a reusable panel PC loaded with bespoke Quadsense software.
• The surgical technique of the device is to take a measurement of the force through the patellofemoral joint at the start of surgery, and then take a comparative measurement of the force through the patellofemoral joint with the trial implants in situ.
• This provides the surgeon with valuable information on how the resurfacing of the femur and tibia has affected the force through the patellofemoral joint.
• The surgeon may then use this information to adjust their positioning of the patella implant.
• The single use sensor is connected to the Panel PC via a cable and the Panel PC sits outside of the sterile field. The sensor is sterilized via ethylene oxide.
• There is a control puck built into the sensor device which allows the surgeon to control the software workflow from within the sterile field.

• The Sonata system is a system for the diagnostic imaging and treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.
• The system consists of a reusable intrauterine ultrasound probe and a single-use disposable radiofrequency ablation handpiece with an introducer and needle electrode.
• These 2 components lock together to form a single treatment device. The intrauterine ultrasound probe is used to identify fibroids from within the uterus and guide the introducer and needle electrodes into one or more targeted fibroids.
• The radiofrequency ablation handpiece is used to deliver radiofrequency energy to the targeted areas to reduce the volume of the fibroids.
• The radiofrequency ablation handpiece also comes with proprietary graphical guidance software.
• This displays a real time graphic overlay on the live ultrasound image to help guide treatment and target ablation zones.

See our Useful Links section for NICE IPG689.

The Impella CP® with SmartAssist Heart Pump® marks a significant advancement in circulatory support technology, offering an innovative solution for patients with severe cardiac conditions. 

This intravascular microaxial blood pump uses real-time intelligence to optimise patient outcomes and enhances the positioning, management, and weaning of the device. Optimally positioned via a percutaneous insertion through the femoral artery or surgically through the axillary artery, the Impella CP with SmartAssist delivers critical support directly to the left ventricle, reducing cardiac workload and improving systemic perfusion with a peak flow of up to 4.3 L/min.

Designed for high-risk percutaneous coronary interventions (PCI) and post-acute myocardial infarction cardiogenic shock (AMI CS), the device supports the circulatory system for up to five days.

See our Useful Links section for NICE IPG633.

The Genedrive System is a point-of-care gene amplification device used for qualitative in vitro molecular diagnostic tests. The company states that the test can detect the *2, *3, *4, *8, *17 and *35 alleles.

The technology consists of:

• Genedrive System analyser, which is a rapid thermocycler capable of polymerase chain reaction (PCR) and isothermal-based amplification techniques.
• Genedrive CYP2C19 ID Kit, which includes an assay cartridge containing reagents, a sample collection cheek swab, a transfer capillary and a collection buffer. The cartridges can be stored at room temperature.

Clopidogrel is an antiplatelet drug used after ischaemic stroke or TIA (sometimes called a ‘mini stroke’) to reduce the risk of blood clots that can cause further strokes. Clopidogrel is metabolised into its active form by an enzyme encoded by a gene called CYP2C19. In some people CYP2C19 has variations that reduce the enzyme’s function (known as ‘loss-of-function’ variants or alleles). This means clopidogrel does not work as well in these people. Testing for these alleles is known as CYP2C19 genotype testing. It aims to identify people with CYP2C19 loss-of-function alleles so they can be offered alternative antiplatelet drugs to lower their risk of blood clots. Testing can be done in a laboratory or at the point of care (for example, on a stroke ward). There is good clinical evidence that people with loss-of-function CYP2C19 alleles who have clopidogrel are more likely to have further strokes compared with people without loss-of-function CYP2C19 alleles. Clinical experts agreed that it would be beneficial to treat people with loss-of-function CYP2C19 alleles with alternative antiplatelet treatment, but the evidence was less clear on the size of this benefit. The economic evidence shows that CYP2C19 genotype testing is cost effective compared with not testing, regardless of which alternative antiplatelet therapy people have. So CYP2C19 genotype testing is recommended.

See our Useful Links section for NICE DG59.

Developed in cooperation with urologists and overactive bladder specialists, and designed with patients, Tensi+ is a non-drug and non-invasive treatment permitting the treatment of overactive bladder of idiopathic or neurological origin.

Fitted on the inner ankle, The Tensi+ medical device uses the transcutaneous electrical nerve stimulation (TENS) technique by stimulating the posterior tibial nerve. The results of the TENS technique are clinically proven after 3 months of treatment, sometimes with the first effects after 6 weeks. It is discreet, simple to fit, and easy to use.